Table 2. Time course of seroprevalence by neutralization assay, Elecsys® Anti-SARS-CoV-2 S, and Elecsys® Anti-SARS-CoV-2.
| Group M n = 84 (n = 80) | Group S n = 62 (n = 47) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days from onset | sample number | Virus neutralization assay | Elecsys® Anti-SARS-CoV-2 S (Elecsys® anti-S) | Elecsys® Anti-SARS-CoV-2 (Elecsys® anti-N) | sample number | Virus neutralization assay | Elecsys® Anti-SARS-CoV-2 S (Elecsys® anti-S) | Elecsys® Anti-SARS-CoV-2 (Elecsys® anti-N) | ||||||
| Positive | % | Positive | % | Positive | % | Positive | % | Positive | % | Positive | % | |||
| 0–6 | 15 (14) | 3 (3) | 20% (21%) | 3 (3) | 20% (21%) | 2(2) | 13% (14%) | 10 (7) | 1 (1) | 10% (14%) | 1 (1) | 10% (14%) | 1 (1) | 10% (14%) |
| 7–13 | 18 (17) | 11 (11) | 61% (65%) | 10 (10) | 56% (59%) | 9 (9) | 50% (53%) | 10 (6) | 5 (5) | 50% (83%) | 5 (5) | 50% (83%) | 5 (5) | 50% (83%) |
| 14–20 | 17 (16) | 16 (16) | 94% (100%) | 16 (16) | 94% (100%) | 11 (11) | 65% (69%) | 9 (7) | 8 (7) | 89% (100%) | 7 (7) | 78% (100%) | 8 (7) | 89% (100%) |
| 21–27 | 12 (11) | 11 (11) | 92% (100%) | 11 (11) | 92% (100%) | 11 (11) | 92% (100%) | 12 (10) | 11 (10) | 92% (100%) | 11 (10) | 92% (100%) | 10 (9) | 83% (90%) |
| 28–34 | 8 (8) | 8 (8) | 100% (100%) | 8 (8) | 100% (100%) | 8 (8) | 100% (100%) | 7 (5) | 6 (5) | 86% (100%) | 6 (5) | 86% (100%) | 6 (5) | 86% (100%) |
| 35–41 | 7 (7) | 7 (7) | 100% (100%) | 7 (7) | 100% (100%) | 7 (7) | 100% (100%) | 6 (4) | 5 (4) | 83% (100%) | 5 (4) | 83% (100%) | 5 (4) | 83% (100%) |
| >42 | 7 (7) | 7 (7) | 100% (100%) | 7 (7) | 100% (100%) | 7 (7) | 100% (100%) | 8 (8) | 8 (8) | 100% (100%) | 8 (8) | 100% (100%) | 8 (8) | 100% (100%) |
Numbers in parenthesis indicate the sample numbers after removing the samples from 3 patients under immunosuppressive therapy.